GAMMA Investing LLC Buys 1,119 Shares of Exelixis, Inc. (NASDAQ:EXEL)

GAMMA Investing LLC grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 37.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,129 shares of the biotechnology company’s stock after buying an additional 1,119 shares during the period. GAMMA Investing LLC’s holdings in Exelixis were worth $137,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in EXEL. Retirement Systems of Alabama lifted its holdings in Exelixis by 24.6% during the third quarter. Retirement Systems of Alabama now owns 911,497 shares of the biotechnology company’s stock valued at $23,653,000 after purchasing an additional 180,021 shares in the last quarter. Tri Ri Asset Management Corp bought a new stake in shares of Exelixis during the 3rd quarter valued at $4,396,000. Tidal Investments LLC raised its position in shares of Exelixis by 2.3% during the 3rd quarter. Tidal Investments LLC now owns 36,366 shares of the biotechnology company’s stock valued at $944,000 after purchasing an additional 823 shares during the period. Sanctuary Advisors LLC lifted its stake in shares of Exelixis by 42.7% during the 3rd quarter. Sanctuary Advisors LLC now owns 39,261 shares of the biotechnology company’s stock valued at $1,019,000 after buying an additional 11,757 shares in the last quarter. Finally, TD Private Client Wealth LLC boosted its holdings in Exelixis by 376.8% in the 3rd quarter. TD Private Client Wealth LLC now owns 9,756 shares of the biotechnology company’s stock worth $253,000 after buying an additional 7,710 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Exelixis news, EVP Dana Aftab sold 1,162 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total value of $36,486.80. Following the completion of the sale, the executive vice president now owns 498,945 shares of the company’s stock, valued at $15,666,873. This trade represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $36.67, for a total value of $2,200,200.00. Following the transaction, the executive vice president now directly owns 486,059 shares in the company, valued at approximately $17,823,783.53. This represents a 10.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 314,736 shares of company stock worth $10,849,110 over the last three months. 2.85% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

EXEL has been the topic of a number of recent analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $34.00 price target on shares of Exelixis in a report on Wednesday, October 30th. The Goldman Sachs Group raised Exelixis to a “strong sell” rating in a report on Tuesday, October 15th. Stifel Nicolaus increased their price objective on shares of Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a report on Wednesday, October 16th. Wells Fargo & Company boosted their target price on shares of Exelixis from $32.00 to $36.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. Finally, JMP Securities restated a “market outperform” rating and set a $29.00 target price on shares of Exelixis in a research report on Friday, October 11th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Exelixis has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

Exelixis Trading Up 0.8 %

EXEL opened at $34.50 on Friday. The stock has a 50-day moving average of $34.84 and a 200 day moving average of $28.71. Exelixis, Inc. has a 12 month low of $20.01 and a 12 month high of $36.97. The firm has a market cap of $9.85 billion, a P/E ratio of 22.12, a P/E/G ratio of 0.88 and a beta of 0.52.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.04. The business had revenue of $539.50 million during the quarter, compared to analyst estimates of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period last year, the company earned $0.10 EPS. On average, research analysts forecast that Exelixis, Inc. will post 1.69 earnings per share for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.